Ruchi Patel

Ruchi Patel

Auto-generated profile, based on publicly available information

Ruchi Patel

Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
YLYong Gu Lee
Yong Gu Lee
PGPuneeth Guruprasad
Puneeth Guruprasad
GGGuido Ghilardi
Guido Ghilardi
RPRaymone Pajarillo
Raymone Pajarillo
CSChristopher Tor Sauter
Christopher Tor Sauter
MRMarco Ruella
Marco Ruella
Chimeric antigen receptor T-cell (CART) immunotherapy led to unprecedented responses in patients with refractory/relapsed B-cell non-Hodgkin lymphoma (NHL); nevertheless, two thirds of patients experience treatment failure. Resistance to apoptosis is a key feature of cancer cells, and it is associated with treatment failure. In 87 patients with NHL treated with anti-CD19 CART, we found that chromosomal alteration of B-cell lymphoma 2 (BCL-2), a critical antiapoptotic regulator, in lymphoma cells was associated with reduced survival. Therefore, we combined CART19 with the FDA-approved BCL-2 inhibitor venetoclax and demonstrated in vivo synergy in venetoclax-sensitive NHL. However, higher venetoclax doses needed for venetoclax-resistant lymphomas resulted in CART toxicity. To overcome this limitation, we developed venetoclax-resistant CART by overexpressing mutated BCL-2(F104L), which is not recognized by venetoclax. Notably, BCL-2(F104L)-CART19 synergized with venetoclax in multiple lymphoma xenograft models. Furthermore, we uncovered that BCL-2 overexpression in T cells intrinsically enhanced CART antitumor activity in preclinical models and in patients by prolonging CART persistence. Significance: This study highlights the role of BCL-2 in resistance to CART immunotherapy for cancer and introduces a novel concept for combination therapies—the engineering of CART cells to make them resistant to proapoptotic small molecules, thereby enhancing the therapeutic index of these combination therapies. This article is highlighted in the In This Issue feature, p. 2221

3 June 2024 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
PGPuneeth Guruprasad
Puneeth Guruprasad
ACAlberto Carturan
Alberto Carturan
YZYunlin Zhang
Yunlin Zhang
JCJong Hyun Cho
Jong Hyun Cho
KKKingsley Gideon Kumashie
Kingsley Gideon Kumashie
MRMarco Ruella
Marco Ruella

19 July 2024 in Science Immunology
Verified
Journal Article
Closed access
RPRuchi P. Patel
Ruchi P. Patel
GGGuido Ghilardi
Guido Ghilardi
YZYunlin Zhang
Yunlin Zhang
YCYi-Hao Chiang
Yi-Hao Chiang
WXWei Xie
Wei Xie
MRMarco Ruella
Marco Ruella
Most patients treated with US Food and Drug Administration (FDA)–approved chimeric antigen receptor (CAR) T cells eventually experience disease progression. Furthermore, CAR T cells have not been curative against solid cancers and several hematological malignancies such as T cell lymphomas, which have very poor prognoses. One of the main barriers to the clinical success of adoptive T cell immunotherapies is CAR T cell dysfunction and lack of expansion and/or persistence after infusion. In this study, we found that CD5 inhibits CAR T cell activation and that knockout (KO) of CD5 using CRISPR-Cas9 enhances the antitumor effect of CAR T cells in multiple hematological and solid cancer models. Mechanistically, CD5 KO drives increased T cell effector function with enhanced cytotoxicity, in vivo expansion, and persistence, without apparent toxicity in preclinical models. These findings indicate that CD5 is a critical inhibitor of T cell function and a potential clinical target for enhancing T cell therapies.

1 February 2019 in Experimental Cell Research
Verified
Journal Article
Closed access
AMAndrew J. McDonald
Andrew J. McDonald
KCKatherine M. Curt
Katherine M. Curt
RPRuchi P. Patel
Ruchi P. Patel
HKHanna Kozlowski
Hanna Kozlowski
DSDan L. Sackett
Dan L. Sackett
SBSusan E. Bates
Susan E. Bates

16 April 2026 in Blood
Verified
Journal Article
Closed access
ACAlberto Carturan
Alberto Carturan
MAMathew Angelos
Mathew Angelos
PGPuneeth Guruprasad
Puneeth Guruprasad
RPRuchi P. Patel
Ruchi P. Patel
RPRaymone Pajarillo
Raymone Pajarillo
MRMarco Ruella
Marco Ruella
Patients with T-cell lymphomas and leukemias have overall poor outcomes because of the lack of targeted and effective treatments, particularly in the relapsed and refractory settings. The development of chimeric antigen receptor (CAR) T cells against T-cell neoplasms is limited by a lack of discriminating T-cell antigens that allow for effective antitumor responses while preventing CAR T-cell fratricide. We hypothesized that targeting CD2, a pan–T-cell antigen, with anti-CD2 CAR T cells engineered to lack CD2 expression (CART2) would improve manufacturability and preclinical efficacy. Optimized CD2-knockout CART2 cells, generated using CRISPR-Cas9, eradicated primary patient-derived CD2+ hematological neoplasms in vitro and in vivo, secreted effector cytokines, and exhibited adequate proliferative capacity. Nevertheless, CD2 has a key costimulatory function, and its deletion could lead to CAR T-cell dysfunction. Therefore, we tested the role of the CD2:CD58 axis in CAR T cells, using the anti-CD19 CART models. We demonstrate that CD2 loss attenuates CART19 efficacy by reducing avidity for tumor antigen, costimulation, and ultimately in vivo activity. Analogously, we show that tumor CD58 loss reduces CART19 efficacy. To overcome this issue, we developed a novel programmed cell death protein 1 (PD-1):CD2 switch receptor that rescues intracellular CD2 signaling, particularly when programmed death-ligand 1 is engaged, thereby improving in vivo outcomes. Collectively, we studied the role of CD2 both as a target for CAR T-cell therapy and as a critical costimulatory protein, whose signaling can be rescued using the PD-1:CD2 switch receptor. This receptor can be incorporated into CAR T cells and provides an effective strategy to overcome CD2-signaling deficiencies.

4 April 2023
Verified
Other
Open access
YLYong Gu Lee
Yong Gu Lee
PGPuneeth Guruprasad
Puneeth Guruprasad
GGGuido Ghilardi
Guido Ghilardi
RPRaymone Pajarillo
Raymone Pajarillo
CSChristopher Tor Sauter
Christopher Tor Sauter
MRMarco Ruella
Marco Ruella
Supplementary Figure from Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer